ArriVent BioPharma, Inc. Common Stock (AVBP) financials · $1.39B cap
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
ArriVent BioPharma, Inc. Common Stock (AVBP) $1.39B cap.
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Income | -$177.5M | -$94.3M |
| Net Income | -$166.3M | -$80.5M |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $333.2M | $274.9M |
| Current Assets | $332.9M | $227.0M |
| Cash & Equivalents | $45.5M | $74.3M |
| Total Liabilities | $25.9M | $17.3M |
| Current Liabilities | $25.9M | $17.3M |
| Shareholders' Equity | $307.2M | $257.7M |
| Retained Earnings | -$404.6M | -$238.3M |
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | -$160.6M | -$70.2M |
| Investing Cash Flow | -$71.2M | -$192.5M |
| Financing Cash Flow | $203.1M | $186.6M |
| Net Change in Cash | -$28.8M | -$76.1M |
FAQ
What is AVBP P/E and revenue?
ArriVent BioPharma, Inc. Common Stock (AVBP) $1.39B cap.
What is AVBP revenue?
AVBP income-statement cache has no revenue figure yet.
Is AVBP profitable?
ArriVent BioPharma, Inc. Common Stock last cached net income is -$166.3M (FY2025).
What are AVBP total assets?
ArriVent BioPharma, Inc. Common Stock last cached total assets are $333.2M (FY2025).
What is AVBP free cash flow?
No cached cash-flow row for AVBP yet.
Not investment advice. Cached statements, not a live tape.